MSLN and ovarian cancer: These results were very encouraging and suggest that the N-terminal 64 amino acids of mesothelin are not only sufficient to facilitate efficient binding to native MUC16, it converts Meso64-TR3 into a much more powerful cancer drug that retains its enhanced in vitro activity profile in a preclinical mouse model of ovarian cancer.